1. Home
  2. PRMB vs BLCO Comparison

PRMB vs BLCO Comparison

Compare PRMB & BLCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Primo Brands Corporation

PRMB

Primo Brands Corporation

N/A

Current Price

$21.41

Market Cap

6.9B

Sector

N/A

ML Signal

N/A

Logo Bausch + Lomb Corporation

BLCO

Bausch + Lomb Corporation

N/A

Current Price

$17.45

Market Cap

6.0B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
PRMB
BLCO
Founded
1955
1853
Country
United States
Canada
Employees
N/A
N/A
Industry
Ophthalmic Goods
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
6.9B
6.0B
IPO Year
N/A
2022

Fundamental Metrics

Financial Performance
Metric
PRMB
BLCO
Price
$21.41
$17.45
Analyst Decision
Buy
Buy
Analyst Count
10
12
Target Price
$28.80
$18.55
AVG Volume (30 Days)
5.3M
454.5K
Earning Date
01-01-0001
05-21-2026
Dividend Yield
2.18%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$5,101,000,000.00
Revenue This Year
$2.31
$8.61
Revenue Next Year
$3.55
$5.52
P/E Ratio
N/A
N/A
Revenue Growth
N/A
6.47
52 Week Low
$14.36
$10.45
52 Week High
$35.85
$18.92

Technical Indicators

Market Signals
Indicator
PRMB
BLCO
Relative Strength Index (RSI) 60.32 46.03
Support Level $15.21 $16.35
Resistance Level $22.96 $17.66
Average True Range (ATR) 0.78 0.52
MACD 0.06 -0.13
Stochastic Oscillator 63.06 23.28

Price Performance

Historical Comparison
PRMB
BLCO

About PRMB Primo Brands Corporation

Primo Brands Corp is a North American branded beverage company focused on healthy hydration. It delivers sustainably and domestically sourced diversified offerings across products, formats, channels, price points, and consumer occasions, distributed in every state and Canada. Primo Brands is in reusable packaging, helping to reduce waste through its reusable, multi-serve bottles and brand packaging portfolio, which includes recycled plastic, aluminum, and glass.

About BLCO Bausch + Lomb Corporation

Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.

Share on Social Networks: